Hemispherx is engaged in the clinical development of new drug entities for the treatment of seriously debilitating disorders

Hemispherx is engaged in the clinical development of new drug entities for the treatment of seriously debilitating disorders

Latest From Hemispherx

  • Hemispherx News 02

CEO Roadshow Interviews Hemispherx Thomas K. Equels

April 4th, 2019|

CEO Roadshow Interviews Hemispherx Thomas K. Equels Hemispherx CEO Thomas K. Equels recently sat down with Mike Elliot of CEO Roadshow to provide an update on everything the company is working at [...]

  • Hemispherx News 04

Introducing You to the First Ampligen Quarterly Update

March 25th, 2019|

Introducing You to the First Ampligen Quarterly Update Today we announced significant progress in our Ampligen pancreatic cancer program and our multiple Ampligen plus checkpoint blockade immuno-oncology programs. We also announced the [...]

Latest From Hemispherx

  • Hemispherx News 02

CEO Roadshow Interviews Hemispherx Thomas K. Equels

April 4th, 2019|

CEO Roadshow Interviews Hemispherx Thomas K. Equels Hemispherx CEO Thomas K. Equels recently sat down with Mike Elliot of CEO Roadshow to provide an update on everything the company is working at [...]

  • Hemispherx News 04

Introducing You to the First Ampligen Quarterly Update

March 25th, 2019|

Introducing You to the First Ampligen Quarterly Update Today we announced significant progress in our Ampligen pancreatic cancer program and our multiple Ampligen plus checkpoint blockade immuno-oncology programs. We also announced the [...]

Want More Info?

Click below for all our contact information

Let’s Talk